Samba BioLogics Selected for MassBio’s Biotech Accelerator, MassBioDrive in Spring 2023 Cohort of Startups
The latest cohort of MassBioDrive, a key initiative of MassBio’s innovation programming designed to support entrepreneurs and…
April 12, 2023
Samba BioLogics, Inc. Awarded NIH SBIR/STTR Program Grant
VasaPlex-based biologics for treatment of reperfusion injury after myocardial infarction.
March 11, 2022
Samba BioLogics Selected for NIH-sponsored DRIVEN Program
Samba BioLogics, Inc. was selected for the NIH-sponsored DRIVEN Program to commercialize our biologics + IP (incubator at Celdara…
April 6, 2020
Spees’ New NIH Grant to Expand Study of Novel Post-Heart Attack Therapy
A heart attack continues to harm cardiac muscle even after the immediate problem – a blocked artery – is fixed, but University of…
August 12, 2016
VasaPlex Featured on WCAX-TV
On August 10, 2016, Jeffrey Spees, PH.D., associate professor in the Division of Cardiovascular Medicine, was featured in a story…
August 10, 2016
SPARK VT Initiative Supports UVM Researchers on the Path to Commercialization
SPARK facilitates the discovery-to-commercialization process for those researchers who, working through UVM Innovations, are have…
March 23, 2014
Priming “Cocktail” Shows Promise as Cardiac Stem Cell Grafting Tool
New research by University of Vermont Associate Professor of Medicine Jeffrey Spees, Ph.D., and colleagues has identified a new…
December 6, 2013
Jeff Spees Guest Appearance Vermont Public Radio (NPR) to Discuss Changes to US Stem Cell Policy
We talk with Jeff Spees, the Director of UVM’s Stem Cell Core facility to learn more about UVM’s research. And we also find out…
December 9, 2009